Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

BACKGROUND: Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study. OBJECTIVE: To compare the efficacy and safety of secukinumab vs. ustekinumab over 52 weeks in CLARI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Eur Acad Dermatol Venereol
Main Authors: Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., de Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Psoriasis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7818402/
https://ncbi.nlm.nih.gov/pubmed/32365251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.16558
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados